Back to top
more

Bausch Health Cos Inc. (BHC)

(Delayed Data from NYSE)

$22.54 USD

22.54
2,945,544

-0.26 (-1.14%)

Updated Oct 18, 2019 04:00 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | D Growth | B Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Implied Volatility Surging for Bausch Health (BHC) Stock Options

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

BHC

Zacks Equity Research

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

NVS INCY TEVA BHC

Zacks Equity Research

Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

PFE FGEN AERI BHC

Zacks Equity Research

Foamix Initiates Phase II Study on Acne Combination Foam

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

FOMX EVOK RDY BHC

Zacks Equity Research

Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

AGN IRWD ARDX BHC

Zacks Equity Research

Why Is Bausch (BHC) Down 4.7% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHC

Zacks Equity Research

Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

AGN IRWD ARDX BHC

Zacks Equity Research

Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?

Is (BHC) Outperforming Other Medical Stocks This Year?

BHC

Zacks Equity Research

Is Bausch Health Cos (BHC) a Good Value Investor Pick?

Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

BHC

Zacks Equity Research

Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

PFE RHHBY AERI BHC

Zacks Equity Research

Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

GALT PTLA BHC ETON

Zacks Equity Research

Bausch Health (BHC) Misses Q2 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of -2.83% and -0.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BHC

Zacks Equity Research

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

RIGL JAZZ ETON BHC

Zacks Equity Research

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHC

Zacks Equity Research

Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

NVS ETON BHC AXGT

Zacks Equity Research

Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHC

Zacks Equity Research

Aerie Completes Enrollment Under Rhopressa Study in Japan

Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

PFE NVS AERI BHC

Zacks Equity Research

Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

ADMS ACST DOVA BHC

Indrajit Bandyopadhyay

Price Stabilization Leads to Generic Drugs Industry's Recovery

Stabilizing prices of generic drugs is leading to a recovery in revenues of industry participants. New launches are also providing a boost. However, competition remains stiff.

BHC ADMS ACST

Zacks Equity Research

Dova Receives Approval for Doptelet in Europe, Stock Up

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

NVS RIGL BHC DOVA

Zacks Equity Research

Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHC

Zacks Equity Research

Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ADMS BHC

Zacks Equity Research

Allergan Up As Analyst Statement Sparks Business Split Rumors

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

LLY AGN BHC EOLS

Zacks Equity Research

Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHC

Zacks Equity Research

Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHC